Business Wire

MA-HOLOGIC

Share
Hologic Releases Results of Inaugural Global Women’s Health Index – First Study Representing the Health of 2.5 Billion Women and Girls

Hologic, Inc. (Nasdaq: HOLX), a global leader in women's health, today shared the findings from its inaugural Hologic Global Women’s Health Index , the world’s most comprehensive, globally comparative survey about women’s health.

Developed in partnership with leading analytics and advice firm Gallup, the Hologic Global Women’s Health Index is an unprecedented, in-depth examination of critical markers for women’s health, by country and territory, and over time. Its findings are based on the experiences of more than 60,000 women and girls from 116 countries and territories, captured in more than 140 languages. Conducted as part of the Gallup World Poll, which began in 2005, the Hologic Global Women’s Health Index represents the feelings and actions of approximately 2.5 billion women and girls.

Based on responses from the 120,000 total individuals surveyed, women’s health needs are not being met globally. The global score was 54 out of 100 on the Index, and no one country or territory scored more than 69. Country and territory rankings can be found here . Notably, 40% of those surveyed – equating to about a billion women and girls – said they had not talked to a healthcare professional in the last year, while approximately 60% – about 1.5 billion – were not tested for four common diseases that affect women’s health.

“Women’s health is the cornerstone of families, communities, societies and economies,” said Steve MacMillan, Hologic’s Chairman, President and Chief Executive Officer. “As a leader in the early detection, diagnosis and treatment of women’s health issues, we know firsthand that measurement is the key to improvement. We saw a clear need for more robust, quality data to track and measure women’s health on a global level — particularly as COVID-19 has worsened longstanding healthcare disparities. The Hologic Global Women’s Health Index is the first global survey that uniquely draws from women’s perspectives to determine priorities.”

The Hologic Global Women’s Health Index provides an actionable, science-backed data roadmap for improving life expectancy and quality of life for women and girls worldwide. To help countries and territories determine a strategy for ensuring a healthy future for women, the Index identifies five dimensions of women’s health that explain more than 80% of women’s average life expectancy at birth: Preventive Care, Opinions of Health and Safety, Emotional Health, Individual Health and Basic Needs. In the Index, countries and territories are ranked across each of these five dimensions, then those scores are combined to create an overall ranking. Positive improvements on any of the five dimensions could potentially help women live healthier, longer lives.

“In line with critical UN Sustainable Development Goals and the UN General Assembly theme of ‘Building Resilience Through Hope,’ we urge global healthcare and government leaders to use this data and the five dimensions to guide the development of actionable and measurable plans and investments that prioritize women’s health,” said MacMillan.

While the Hologic Global Women’s Health Index was initiated before COVID-19 affected the world, the pandemic and its effects on the already precarious state of women’s healthcare — including postponed or canceled preventive care examinations, increased poverty levels, and insufficient access to medical facilities and education — have created a more urgent need for world leaders and policymakers to prioritize women’s health.

“The COVID-19 pandemic has both exacerbated and shed light on longstanding gaps in access and quality of healthcare,” said Vipula Gandhi, Senior Managing Partner at Gallup. “The Index provides a baseline from which we can measure the state of women’s health globally. We hope this study will serve as a call to action for world leaders and policymakers as they navigate the global recovery.”

Hologic is committed to conducting the Global Women’s Health Index on a regular basis so world leaders can take action. This commitment builds on Hologic’s more than 30 years of championing women’s health around the world through its products for breast and cervical cancer screening, infectious disease detection, and gynecologic surgery, and its partnerships with numerous global initiatives promoting better access to healthcare .

Country and Territory Rankings Influenced by Disparities in Income and Health Systems

In this first year of the Hologic Global Women’s Health Index, no single country or territory scored more than 69 out of 100. Generally, most countries and territories that lead the world on the Index also lead the world in how much of their wealth they invest back into their health systems, including Austria, Switzerland and Norway. Overall, while women in high-income countries and territories were only 17% of the women surveyed in the Index, they collectively have at least a seven-point lead on the Index over all other women globally.

Conversely, the countries and territories with the lowest scores on the Hologic Global Women’s Health Index all share high income inequality and weak or destabilized infrastructure for healthcare. The countries and territories with the lowest scores on the Index are a mix of mostly low- and lower-middle income economies. Few countries and territories in this group score well in meeting women’s basic needs and are significantly lagging in the Preventive Care dimension.

Universal Challenges Around Preventive Care

“Preventive measures are a crucial first step to combating diseases and infections affecting life expectancy and fertility in women,” said Susan Harvey, MD, Vice-President of Global Medical Affairs, Hologic. “Failing to ensure women get routine testing for cancers, sexually transmitted diseases and infections, and cardiometabolic diseases can lead to larger complications that would otherwise be preventable if monitored or treated early.”

While international testing standards differ, the Hologic Global Women’s Health Index found that within the past 12 months, more than 1.5 billion women were not tested for any of four critical diseases for women: cancer, diabetes, high blood pressure and sexually transmitted diseases/infections (STDs/STIs).

  • Just 12% of women worldwide reported being screened for any type of cancer.
  • Globally, only about one in five (19%) women reported being screened for diabetes, the sixth leading cause of death for women around the world. In countries and territories with high obesity rates such as the United States, one in three women (34%) reported being tested.
  • On average, only one in three women (33%) worldwide had their blood pressure tested despite heart disease being the leading cause of death globally for women and men.
  • Fewer than one in nine women (11%) reported being tested for STDs/STIs, which are risk factors for further health issues like HIV, cancer and infertility. 

A Holistic Approach to Women’s Health

Collectively, the world in 2020 felt the worst it has in 15 years. Global experiences of worry, stress, sadness and anger continued to rise and set new records. About four in ten women said they experienced worry (40%) and stress (38%) during a lot of the previous day.

Many women surveyed also expressed concerns about their safety and ability to meet basic needs like food and shelter.

  • Two in three women (66%) — which translates into roughly 1.7 billion women — cited domestic violence as a widespread problem in their country.
  • Nearly one in three (32%) — more than 800 million women — said they are afraid to walk alone at night.
  • More than one in three (34%) — nearly 900 million women — said they struggled to afford food in the past year.
  • Nearly three in ten (29%) — or nearly 700 million women — said they struggled to afford adequate housing for themselves and their families.

For more information about the Hologic Global Women’s Health Index and year one findings, please visit hologic.womenshealthindex.com .

About Hologic, Inc.

Hologic, Inc. is an innovative medical technology company primarily focused on improving women’s health and well-being through early detection and treatment. For more information on Hologic, visit www.hologic.com .

Hologic and the Global Women’s Health Index are trademarks and/or registered trademarks of Hologic, Inc., and/or its subsidiaries in the United States and/or other countries and territories.

About the Gallup World Poll

The Gallup World Poll is the most comprehensive and farthest-reaching survey of the world. The survey connects with more than 90% of the world's adult population through annual, nationally representative surveys with comparable metrics across countries and territories. Gallup, Inc. works with organizations across multilaterals, NGOs, private foundations, philanthropies and corporations to measure more than 100 crucial issues affecting people's lives via the World Poll. As a result, the World Poll has become an indispensable tool for global leaders and decision-makers who need to understand the hopes, dreams and behaviors of the people they serve.

Forward Looking Statements

This news release may contain forward-looking information that involves risks and uncertainties, including statements about the Company’s plans, objectives, expectations and intentions. There can be no assurance that these efforts will be successful, benefit the Company and its stockholders, or improve over time. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any changes in expectations or events, conditions or circumstances on which any such data or statements are based.

SOURCE : Hologic, Inc.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Blue Matter Establishes New Capabilities in Biopharma Research & Development Led by Partner, Tara Austraat-Churik13.1.2026 15:01:00 CET | Press release

Blue Matter is pleased to announce that it has established a practice area dedicated to serving clients in biopharmaceutical Research & Development (R&D). The practice is led by Tara Austraat-Churik, a Partner who joined the firm in September 2025. Tara Austraat-Churik has been serving life science clients for more than 20 years. Her areas of expertise include strategy development and implementation, operating model and organizational design, and process optimization in R&D and Medical Affairs. Prior to joining Blue Matter, she served as Managing Director in R&D, Health, Science, and Wellness at EY. She has a robust background in consulting, which also includes roles at Booz Allen Hamilton, Navitas, WPP, and IBM. She holds a BA and MA from the University of Notre Dame and an MSc in Translational Medicine from the University of Edinburgh. The R&D practice, according to Austraat-Churik, exists to help biopharma companies simplify and accelerate the pathway to market. She adds, “R&D organ

Wasabi Raises $70M in New Equity to Power the Next Era of Data Infrastructure13.1.2026 15:00:00 CET | Press release

At a $1.8 billion valuation, backed by L2 Point and Pure Storage, the company scales AI-first cloud storage to meet the explosive demands of modern data Wasabi Technologies, the Hot Cloud Storage company, today announced a $70 million equity funding round led by L2 Point Management with participation from Pure Storage and existing investors including Fidelity Management & Research Company. The new round values Wasabi at $1.8 billion and brings the company’s total funding to over $600 million. The capital will be used to accelerate Wasabi’s expansion into AI infrastructure, broaden its global footprint, and enhance its product portfolio to meet the growing data demands of enterprises and AI developers worldwide. “We’re ushering in the next generation of cloud storage, powering data-intensive workloads like generative AI and autonomous systems,” said David Friend, co-founder and CEO of Wasabi Technologies. “This funding underscores Wasabi’s strong market position and continued growth as

HumanX Amsterdam Reveals First 100 Speakers, Bringing Global AI Powerhouses to Europe13.1.2026 14:00:00 CET | Press release

Anton Osika (Lovable), May Habib (Writer), Jan Oberhauser (n8n) & Eléonore Crespo (Pigment) headline a diverse lineup spanning AI innovation and enterprise adoption HumanX, the global AI summit for executives and innovators, today unveiled its first 100 speakers and opened registration for HumanX Amsterdam, taking place 22–24 September 2026 at The RAI. Built by the team behind Money20/20, Shoptalk, and HLTH, HumanX Amsterdam brings the proven formula of its #1 U.S. flagship event and ecosystem gathering to Europe. The event convenes over 2,500 senior leaders focused on moving beyond the hype to drive practical, responsible AI implementation across industries. Speakers Leading the Conversation The first 100 speakers include AI company founders such as Anton Osika (Lovable), Jan Oberhauser (n8n), May Habib (Writer), Arvind Jain (Glean), and Jarek Kutylowski (DeepL), alongside executives scaling AI in the enterprise, including Clay Bavor (Sierra), Des Traynor (Intercom), and Eléonore Cres

GARDP and Debiopharm Partner to Advance Development of Novel Gonorrhea Drug13.1.2026 14:00:00 CET | Press release

The GARDP Foundation (known as GARDP) and the privately-owned, global biopharmaceutical company Debiopharm today announced that they have entered into a collaboration and license agreement to pursue the development of Debio1453, a novel, first-in-class antibiotic targeting Neisseria gonorrhoeae. With 82 million new cases each year, and the continued spread of multidrug-resistant N. gonorrhoeae strains, gonorrhea represents a global health crisis. This new partnership will help ensure that gonorrhea continues to be a treatable disease and will alleviate the risk of the emergence of future resistance, by ensuring that the antibiotic pipeline continues to be replenished. Gonorrhea caused by N. gonorrhoeae is currently in danger of becoming untreatable because of antimicrobial resistance (AMR). Having developed resistance to almost all antibiotics used to treat it, only one last recommended treatment, ceftriaxone, remains effective, and now we are seeing a growing number of cases that are

Wolfspeed Achieves 300mm Silicon Carbide (SiC) Technology Breakthrough13.1.2026 14:00:00 CET | Press release

300mm SiC Technology, Enabling Scalable Platforms for AI Infrastructure, AR/VR, and Advanced Power DevicesAnnouncement highlights:Strategic Technology Milestone – Wolfspeed has produced a single crystal 300mm (12-inch) silicon carbide wafer, representing a major advancement in the evolution of silicon carbide technology and a critical enabler for emerging applications. Technology leadership for Next-Gen Applications – Backed by one of the industry’s largest and most foundational silicon carbide IP portfolios, with over 2,300 issued and pending patents worldwide, Wolfspeed is accelerating the commercialization of 300mm technology to power next-generation platforms including AI infrastructure, augmented reality/virtual reality (AR/VR) and advanced power devices. Strengthening U.S. Semiconductor Leadership & Supply Chain Resilience –The company’s vertically integrated supply chain, from crystal growth to advanced packaging, supports national goals around compound semiconductor independenc

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye